Ruthenium-based nitric oxide-donating and carbon monoxide-donating molecules
- 1 March 2016
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 68 (3) , 293-304
Abstract
Objectives: Over the past few years, the use of metallocomplexes for medical purposes has considerably grown. Because of its favourable characteristics, ruthenium has taken a significant place in this expanding field of research. Several ruthenium-containing metal compounds have been developed as delivery agents of physiological important molecules such as nitric oxide (NO) and carbon monoxide (CO). Key findings: This review focuses on the (vaso)relaxant capacity of ruthenium-based NO-donating and CO-donating molecules in view of their potential usefulness in the treatment of cardiovascular diseases and erectile dysfunction. Summary: Ruthenium seems to be a valuable candidate for the design of NO-donating and CO-donating molecules. To date, ruthenium remains of interest in drug research as the search for new alternatives is still necessary.Keywords
This publication has 94 references indexed in Scilit:
- Metallodrugs in Medicinal Inorganic ChemistryChemical Reviews, 2014
- Ru(II)-Based Antimicrobials: Looking Beyond Organic DrugsMini-Reviews in Medicinal Chemistry, 2012
- Biological activity of ruthenium nitrosyl complexesNitric Oxide, 2012
- Novel Metals and Metal Complexes as Platforms for Cancer TherapyCurrent Pharmaceutical Design, 2010
- Ruthenium (II) phosphine/picolinate complexes as antimycobacterial agentsEuropean Journal of Medicinal Chemistry, 2010
- Recent developments in ruthenium anticancer drugsMetallomics, 2009
- Metal based drugs: from serendipity to designDalton Transactions, 2007
- In vitro immunomodulatory activity of ruthenium complexesInflammation Research, 2003
- Medicinal Inorganic Chemistry: IntroductionChemical Reviews, 1999
- Metal Compounds in Therapy and DiagnosisScience, 1993